Park Yeon Hee, Lee Se-Hoon, Kim Won Seog, Bang Soo-Mee, Ryoo Baek-Yeol, Yang Sung Hyun, Lee Seung-Sook, Kim Mi Sook, Kim Kihyun, Park Keon Woo, Im Do Hyoung, Kang Jung Hun, Lee Jeeyun, Ko Young H, Ahn Yong Chan, Lim Do Hoon, Park Keunchil
Department of Hematology-Oncology, Korea Institute of Radiological & Medical Sciences, Seoul, Korea.
Leuk Lymphoma. 2006 Jul;47(7):1253-9. doi: 10.1080/10428190600556239.
We aimed to define the role of cyclophosphamide, vincristine, doxorubicin, prednisone (CHOP) followed by involved field radiotherapy (IFRT) for treating localized primary gastric diffuse large B-cell lymphoma (DLBCL). Newly diagnosed patients with localized primary gastric DLBCL were to receive four cycles of CHOP followed by IFRT of 40.0 Gy. At 1 year after the completion of treatment, patients filled out the EORTC Quality of Life Questionnaire specified for stomach cancer (QLQ-C30-STO22). Fifty evaluable patients (25 men, 25 women) were included. The median age was 54.5 years (range, 21 - 73 years. The overall response rate to the CHOP was 94% (95% confidence interval [CI], 87 - 100) in the intent-to-treat population. Forty-one of the 50 patients (82%; 95% CI, 71 - 93) achieved complete remission (CR). After the completion of radiotherapy, five patients who were in PR following chemotherapy eventually attained CR. The overall complete response rate was thus 92% (95% confidence interval, 84 - 99). With a median follow-up period of 30 months, the 2-year progression-free and overall survival rate was 92% and 92%, respectively. The gastric function was well preserved with negligible stomach-related symptoms at 1 year after the completion of treatment. This organ-preserving combined treatment is highly effective and well tolerated for the patients with localized gastric DLBCL.
我们旨在明确环磷酰胺、长春新碱、多柔比星、泼尼松（CHOP方案）序贯受累野放疗（IFRT）在治疗局限性原发性胃弥漫性大B细胞淋巴瘤（DLBCL）中的作用。新诊断的局限性原发性胃DLBCL患者接受4个周期的CHOP方案治疗，随后进行40.0 Gy的IFRT。在治疗完成1年后，患者填写欧洲癌症研究与治疗组织（EORTC）指定的胃癌生活质量问卷（QLQ-C30-STO22）。纳入了50例可评估患者（25例男性，25例女性）。中位年龄为54.5岁（范围21 - 73岁）。在意向性治疗人群中，CHOP方案的总体缓解率为94%（95%置信区间[CI]，87 - 100）。50例患者中有41例（82%；95% CI，71 - 93）达到完全缓解（CR）。放疗完成后，5例化疗后处于部分缓解（PR）的患者最终达到CR。因此总体完全缓解率为92%（95%置信区间，84 - 99）。中位随访期为30个月，2年无进展生存率和总生存率分别为92%和92%。治疗完成1年后胃功能保存良好，与胃相关的症状可忽略不计。这种保留器官的联合治疗对局限性胃DLBCL患者高效且耐受性良好。
